5 completed, 3 recruiting, 3 terminated. 7 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Recruiting 2, Terminated 2 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Corbus Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC) | Phase 3 | Recruiting | Corbus Pharmaceuticals Inc. | 260 | 2026-09-29 | 2026-10-08 |
| A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity CRB-913, Placebo - Obese But Otherwise Healthy Participants | Phase 1 | Completed | Corbus Pharmaceuticals Inc. | 254 | 2025-12-04 | 2026-10-09 |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Corbus Pharmaceuticals Inc. | 156 | 2024-12-04 | 2025-06-03 |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors CRB-701, Anti-PD-1 - Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Corbus Pharmaceuticals Inc. | 348 | 2024-04-01 | 2026-01-08 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Lenabasum 20 mg, Lenabasum 5 mg, Placebo - Dermatomyositis | Phase 3 | Completed | Corbus Pharmaceuticals Inc. | 176 | 2018-12-17 | 2022-08-16 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis Lenabasum 20 mg, Lenabasum 5 mg, Placebo - Cystic Fibrosis | Phase 2 | Completed | Corbus Pharmaceuticals Inc. | 447 | 2017-12-22 | 2023-01-18 |
| JBT-101 in Systemic Lupus Erythematosus (SLE) JBT-101, Placebo - Systemic Lupus Erythematosus, SLE | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 109 | 2017-12-21 | 2026-05-06 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule - Diffuse Cutaneous Systemic Sclerosis | Phase 3 | Terminated | Corbus Pharmaceuticals Inc. | 365 | 2017-12-18 | 2021-03-29 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis JBT-101 (lenabasum), Placebo - Cystic Fibrosis | Phase 2 | Completed | Corbus Pharmaceuticals Inc. | 85 | 2015-09-29 | 2018-04-04 |
| Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis JBT-101, Placebo, Part B Open-Label Extension - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Corbus Pharmaceuticals Inc. | 42 | 2015-08-01 | 2021-04-21 |
| Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis JBT-101, Placebo - Dermatomyositis | Phase 2 | Terminated | Corbus Pharmaceuticals Inc. | 22 | 2015-06-01 | 2023-01-19 |
Cystic Fibrosis (2) · Dermatomyositis (2) · Scleroderma, Diffuse (2) · Body Weight (1) · Endocrine System Diseases (1) · Lupus Erythematosus, Systemic (1) · Metabolic Diseases (1) · Musculoskeletal Diseases (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Obesity (1) · Oropharyngeal Neoplasms (1) · Overweight (1) · Scleroderma, Systemic (1) · Squamous Cell Carcinoma of Head and Neck (1)
lenabasum (6) · anabasum (2) · spartalizumab (2) · Cetuximab (1) · Docetaxel (1)
United States (11) · United Kingdom (7) · Germany (5) · Italy (5) · Spain (5) · Canada (4) · France (4) · Poland (4) · Belgium (3) · Hungary (3) · Romania (3) · South Korea (3) · Austria (2) · Bulgaria (2) · Czechia (2)
Ari Rosenberg, MD (2) · Cesar Peres, MD (1) · Chester V Oddis, MD (1) · Chris Denton, MD (1) · Christian Ottensmeier, MD (1) · David Pinato, MD (1) · Dominic Smethurst, MD (1) · Ian Hodgson, PhD (1) · J S Elborn, M.D. (1) · J. Stuart Elborn, MD (1) · James Chmiel, M.D. (1) · James Chmiel, MD (1) · Jeff Clarke, MD (1) · Leela Vrishabhendra, MD (1) · Meggan Mackay, M.D., M.S. (1)
PMID 33011099, PMID 35490744, PMID 39403556, PMID 40383862
R21AR066286 (1), UM1AI110494 (1)